Autologous renal cell cancer vaccines using heat shock protein-peptide complexes

被引：17

作者：

Aalamian, Maryam

Fuchs, Ephraim

Gupta, Renu

Levey, Daniel L. ^{[1
]}

机构：

[1] Antigen Inc, Lexington, MA 02421 USA

[2] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2006年 / 24卷 / 05期

关键词：

heat shock protein; autologous; renal cell carcinoma;

D O I：

10.1016/j.urolonc.2005.08.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Investigations into the role of heat shock proteins (HSPs) in immune response have progressed well into a third decade, and indications of their use for the treatment of renal cell carcinoma (RCC) in the adjuvant setting will be revealed in the near future when a randomized phase III clinical trial is completed. Additional ongoing and planned randomized clinical trials will test the efficacy of HSP-based vaccines in more advanced stages of RCC. This review describes the compelling scientific rationale behind testing HSPs in RCC against the backdrop of other immunotherapeutic approaches in this indication. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：425 / 433

页数：9

共 98 条

[31]

GUOBJARTSSON T, 1995, SCAND J UROL NEPHROL, V29, P215

[32] The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins [J].